Oppenheimer raised its price target on TherapeuticsMD (NASDAQ: TXMD) to $12.00 (from $10.00) while maintaining a Outperform rating.Analyst Jay Olson ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a SympMay 30, 2018 9:38 AM Pre-Open Movers 05/30: (DKS) (MOV) (TXMD) Higher; (CHS) (TTOO) (KORS) Lower (more...)May 30, 2018 9:19 AM Form 8-K TherapeuticsMD, Inc. For: May 30May 30, 2018 6:07 AM TherapeuticsMD (TXMD) Secures FDA Approval for TX-004HRMay 30, 2018 6:06 AM TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a SymptomMay 30, 2018 6:00 AM